179 related articles for article (PubMed ID: 29136403)
1. High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
Lam JUH; Elfström KM; Ejegod DM; Pedersen H; Rygaard C; Rebolj M; Lynge E; Juul KE; Kjær SK; Dillner J; Bonde J
Br J Cancer; 2018 Jan; 118(1):138-144. PubMed ID: 29136403
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
4. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.
Polman NJ; Ebisch RMF; Heideman DAM; Melchers WJG; Bekkers RLM; Molijn AC; Meijer CJLM; Quint WGV; Snijders PJF; Massuger LFAG; van Kemenade FJ; Berkhof J
Lancet Oncol; 2019 Feb; 20(2):229-238. PubMed ID: 30658933
[TBL] [Abstract][Full Text] [Related]
5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches.
Ivanus U; Jerman T; Fokter AR; Takac I; Prevodnik VK; Marcec M; Gajsek US; Pakiz M; Koren J; Celik SH; Kramberger KG; Klopcic U; Kavalar R; Zatler SS; Kuzmanov BG; Florjancic M; Nolde N; Novakovic S; Poljak M; Zakelj MP
Radiol Oncol; 2018 Sep; 52(4):399-412. PubMed ID: 30216191
[TBL] [Abstract][Full Text] [Related]
7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
9. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
[TBL] [Abstract][Full Text] [Related]
11. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
13. [A feasibility study on cervical screening in non-attenders invited to undergo HPV self-sampling with cytology triage versus repeat invitation for cytology screening in Hokkaido].
Taniguchi S; Sakuragi N; Hanley SJB; Tsukiyama K; Fujita H; Sagae S; Kajii N; Watari H; Tamakoshi A
Nihon Koshu Eisei Zasshi; 2021 Dec; 68(11):719-727. PubMed ID: 34373426
[TBL] [Abstract][Full Text] [Related]
14. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
15. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
El-Zein M; Bouten S; Louvanto K; Gilbert L; Gotlieb W; Hemmings R; Behr MA; Franco EL;
Gynecol Oncol; 2018 Jun; 149(3):491-497. PubMed ID: 29678360
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
17. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.
Lindell M; Sanner K; Wikström I; Wilander E
BJOG; 2012 Jan; 119(2):245-8. PubMed ID: 22017806
[TBL] [Abstract][Full Text] [Related]
18. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
19. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.
Arrossi S; Paolino M; Laudi R; Gago J; Campanera A; Marín O; Falcón C; Serra V; Herrero R; Thouyaret L
Lancet Glob Health; 2019 Jun; 7(6):e772-e783. PubMed ID: 31097279
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
